Matches in SemOpenAlex for { <https://semopenalex.org/work/W1480979522> ?p ?o ?g. }
- W1480979522 endingPage "2221" @default.
- W1480979522 startingPage "2206" @default.
- W1480979522 abstract "// Stefania Cannito 1,* , Cristian Turato 2,* , Claudia Paternostro 1 , Alessandra Biasiolo 2 , Sebastiano Colombatto 3 , Irene Cambieri 4 , Santina Quarta 2 , Erica Novo 1 , Elisabetta Morello 1 , Gianmarco Villano 2 , Silvano Fasolato 2 , Tiziana Musso 5 , Ezio David 6 , Ignazia Tusa 7 , Elisabetta Rovida 7 , Riccardo Autelli 1 , Antonina Smedile 8 , Umberto Cillo 9 , Patrizia Pontisso 2 and Maurizio Parola 1 1 Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Interuniversity Center for Liver Pathophysiology, University of Torino, Italy 2 Department of Medicine, University of Padova, Italy 3 Department of Oncology, University of Torino, Italy 4 Department of Plastic Surgery and Burn Unit Skin Bank, CTO Hospital, Torino, Italy 5 Department of Public Health and Pediatric Sciences, University of Torino, Italy 6 Pathology Unit, San Giovanni Battista Hospital, Torino, Italy 7 Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Firenze, Italy 8 Gastroenterology and Hepatology Division, San Giovanni Battista Hospital, Torino, Italy 9 Unit of Hepatobiliary Surgery and Liver Transplantation, University of Padova, Italy * These authors contributed equally to this work Correspondence: Maurizio Parola, email: // Keywords : SERPINB3, hypoxia, hepatocellular carcinoma, HIF-2α, reactive oxygen species Received : September 01, 2014 Accepted : December 09, 2014 Published : December 10, 2014 Abstract SERPINB3 is a cysteine-proteases inhibitor up-regulated in a significant number of cirrhotic patients carrying hepatocellular carcinoma (HCC) and recently proposed as a prognostic marker for HCC early recurrence. SERPINB3 has been reported to stimulate proliferation, inhibit apoptosis and, similar to what reported for hypoxia, to trigger epithelial-to-mesenchymal transition (EMT) and increased invasiveness in liver cancer cells. This study has investigated whether SERPINB3 expression is regulated by hypoxia-related mechanisms in liver cancer cells. Exposure of HepG2 and Huh7 cells to hypoxia up-regulated SERPINB3 transcription, protein synthesis and release in the extracellular medium. Hypoxia-dependent SERPINB3 up-regulation was selective (no change detected for SERPINB4) and operated through hypoxia inducible factor (HIF)-2α (not HIF-1α) binding to SERPINB3 promoter, as confirmed by chromatin immuno-precipitation assay and silencing experiments employing specific siRNAs. HIF-2α-mediated SERPINB3 up-regulation under hypoxic conditions required intracellular generation of ROS. Immuno-histochemistry (IHC) and transcript analysis, performed in human HCC specimens, revealed co-localization of the two proteins in liver cancer cells and the existence of a positive correlation between HIF-2α and SERPINB3 transcript levels, respectively. Hypoxia, through HIF-2α-dependent and redox-sensitive mechanisms, up-regulates the transcription, synthesis and release of SERPINB3, a molecule with a high oncogenic potential." @default.
- W1480979522 created "2016-06-24" @default.
- W1480979522 creator A5000328992 @default.
- W1480979522 creator A5001801914 @default.
- W1480979522 creator A5002308510 @default.
- W1480979522 creator A5004773206 @default.
- W1480979522 creator A5009741003 @default.
- W1480979522 creator A5011054380 @default.
- W1480979522 creator A5016122300 @default.
- W1480979522 creator A5020501583 @default.
- W1480979522 creator A5027182053 @default.
- W1480979522 creator A5028004378 @default.
- W1480979522 creator A5031576111 @default.
- W1480979522 creator A5034856491 @default.
- W1480979522 creator A5058540507 @default.
- W1480979522 creator A5062883623 @default.
- W1480979522 creator A5065210915 @default.
- W1480979522 creator A5067656521 @default.
- W1480979522 creator A5067846459 @default.
- W1480979522 creator A5083316224 @default.
- W1480979522 creator A5085549187 @default.
- W1480979522 creator A5088831381 @default.
- W1480979522 date "2014-12-10" @default.
- W1480979522 modified "2023-09-27" @default.
- W1480979522 title "Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells" @default.
- W1480979522 cites W1493048246 @default.
- W1480979522 cites W1965249067 @default.
- W1480979522 cites W1967913719 @default.
- W1480979522 cites W1968077710 @default.
- W1480979522 cites W1971514499 @default.
- W1480979522 cites W1973541913 @default.
- W1480979522 cites W1975514993 @default.
- W1480979522 cites W1990607537 @default.
- W1480979522 cites W1998664010 @default.
- W1480979522 cites W1999335215 @default.
- W1480979522 cites W2000787663 @default.
- W1480979522 cites W2000849614 @default.
- W1480979522 cites W2011202818 @default.
- W1480979522 cites W2014245338 @default.
- W1480979522 cites W2017439842 @default.
- W1480979522 cites W2022451432 @default.
- W1480979522 cites W2027852965 @default.
- W1480979522 cites W2029375108 @default.
- W1480979522 cites W2033474573 @default.
- W1480979522 cites W2039298921 @default.
- W1480979522 cites W2040176379 @default.
- W1480979522 cites W2040856926 @default.
- W1480979522 cites W2042043279 @default.
- W1480979522 cites W2042198997 @default.
- W1480979522 cites W2047128394 @default.
- W1480979522 cites W2068149517 @default.
- W1480979522 cites W2069698188 @default.
- W1480979522 cites W2070261550 @default.
- W1480979522 cites W2074269538 @default.
- W1480979522 cites W2087408685 @default.
- W1480979522 cites W2090786698 @default.
- W1480979522 cites W2108171080 @default.
- W1480979522 cites W2110085982 @default.
- W1480979522 cites W2116263694 @default.
- W1480979522 cites W2117779825 @default.
- W1480979522 cites W2118655588 @default.
- W1480979522 cites W2124496728 @default.
- W1480979522 cites W2132892999 @default.
- W1480979522 cites W2136875815 @default.
- W1480979522 cites W2137052325 @default.
- W1480979522 cites W2146267383 @default.
- W1480979522 cites W2147230623 @default.
- W1480979522 cites W2151029652 @default.
- W1480979522 cites W2154589460 @default.
- W1480979522 cites W2158367867 @default.
- W1480979522 cites W2161483331 @default.
- W1480979522 cites W2171215167 @default.
- W1480979522 cites W2186266682 @default.
- W1480979522 cites W2466426028 @default.
- W1480979522 cites W2580449060 @default.
- W1480979522 cites W4211105405 @default.
- W1480979522 doi "https://doi.org/10.18632/oncotarget.2943" @default.
- W1480979522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4385846" @default.
- W1480979522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25544768" @default.
- W1480979522 hasPublicationYear "2014" @default.
- W1480979522 type Work @default.
- W1480979522 sameAs 1480979522 @default.
- W1480979522 citedByCount "51" @default.
- W1480979522 countsByYear W14809795222015 @default.
- W1480979522 countsByYear W14809795222016 @default.
- W1480979522 countsByYear W14809795222017 @default.
- W1480979522 countsByYear W14809795222018 @default.
- W1480979522 countsByYear W14809795222019 @default.
- W1480979522 countsByYear W14809795222020 @default.
- W1480979522 countsByYear W14809795222021 @default.
- W1480979522 countsByYear W14809795222022 @default.
- W1480979522 countsByYear W14809795222023 @default.
- W1480979522 crossrefType "journal-article" @default.
- W1480979522 hasAuthorship W1480979522A5000328992 @default.
- W1480979522 hasAuthorship W1480979522A5001801914 @default.
- W1480979522 hasAuthorship W1480979522A5002308510 @default.
- W1480979522 hasAuthorship W1480979522A5004773206 @default.
- W1480979522 hasAuthorship W1480979522A5009741003 @default.